AU2023210844A1 - Activatable bispecific anti-cd47 and anti-pd-l1 proteins and uses thereof - Google Patents

Activatable bispecific anti-cd47 and anti-pd-l1 proteins and uses thereof Download PDF

Info

Publication number
AU2023210844A1
AU2023210844A1 AU2023210844A AU2023210844A AU2023210844A1 AU 2023210844 A1 AU2023210844 A1 AU 2023210844A1 AU 2023210844 A AU2023210844 A AU 2023210844A AU 2023210844 A AU2023210844 A AU 2023210844A AU 2023210844 A1 AU2023210844 A1 AU 2023210844A1
Authority
AU
Australia
Prior art keywords
cancer
seq
protein
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023210844A
Other languages
English (en)
Inventor
William James Jonathan Finlay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centessa Pharmaceuticals UK Ltd
Original Assignee
Centessa Pharmaceuticals UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centessa Pharmaceuticals UK Ltd filed Critical Centessa Pharmaceuticals UK Ltd
Publication of AU2023210844A1 publication Critical patent/AU2023210844A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2023210844A 2022-01-31 2023-01-31 Activatable bispecific anti-cd47 and anti-pd-l1 proteins and uses thereof Pending AU2023210844A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202263305003P 2022-01-31 2022-01-31
US63/305,003 2022-01-31
US202263309759P 2022-02-14 2022-02-14
US63/309,759 2022-02-14
US202263342283P 2022-05-16 2022-05-16
US63/342,283 2022-05-16
US202263348842P 2022-06-03 2022-06-03
US63/348,842 2022-06-03
PCT/EP2023/052366 WO2023144423A1 (en) 2022-01-31 2023-01-31 Activatable bispecific anti-cd47 and anti-pd-l1 proteins and uses thereof

Publications (1)

Publication Number Publication Date
AU2023210844A1 true AU2023210844A1 (en) 2024-08-01

Family

ID=85199086

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023210844A Pending AU2023210844A1 (en) 2022-01-31 2023-01-31 Activatable bispecific anti-cd47 and anti-pd-l1 proteins and uses thereof

Country Status (9)

Country Link
US (1) US20250002585A1 (https=)
EP (1) EP4473012A1 (https=)
JP (1) JP2025504955A (https=)
KR (1) KR20240137084A (https=)
AU (1) AU2023210844A1 (https=)
CA (1) CA3251615A1 (https=)
IL (1) IL314395A (https=)
MX (1) MX2024009251A (https=)
WO (1) WO2023144423A1 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
CN111212852A (zh) 2017-08-18 2020-05-29 超人肆有限公司 结合剂
US20240124889A1 (en) * 2019-05-07 2024-04-18 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
GB201906685D0 (en) * 2019-05-13 2019-06-26 Ultrahuman Six Ltd Activatable protein constructs and uses thereof
CN116390939A (zh) * 2020-08-04 2023-07-04 埃克塞里艾克西斯公司 多重特异性结合剂及其用途

Also Published As

Publication number Publication date
IL314395A (en) 2024-09-01
JP2025504955A (ja) 2025-02-19
US20250002585A1 (en) 2025-01-02
MX2024009251A (es) 2024-08-06
CA3251615A1 (en) 2023-08-03
EP4473012A1 (en) 2024-12-11
WO2023144423A1 (en) 2023-08-03
KR20240137084A (ko) 2024-09-19

Similar Documents

Publication Publication Date Title
EP3535298B1 (en) Antibodies to pd-1 and uses thereof
AU2022203620A1 (en) Therapeutic antibodies and their uses
CN107735105B (zh) 抗ntb-a抗体和相关组合物以及方法
KR20220008841A (ko) 인간 면역글로불린 힌지 영역인 두 개의 결합 도메인 사이의 링커 또는 이의 변이체를 포함하는 활성화 가능한 이중특이성 항체 및 이의 용도
AU2022256455A9 (en) Anti-cd122 antibodies and uses thereof
RS66837B1 (sr) Agensi sa dvostrukim vezivanjem za pd1 i vegfr2
CA3218086A1 (en) New stable anti-vista antibody
US20230272082A1 (en) Anti-vista antibodies and uses thereof
EP4562037A1 (en) Bispecific anti-c-kit and anti-cd203c antigen-binding molecules and uses thereof
US20250109206A1 (en) Activatable bispecific anti-cd3 and anti-pd-l1 proteins and uses thereof
CA3091307A1 (en) Csf1r binding agents
US20250002585A1 (en) Activatable bispecific anti-cd47 and anti-pd-l1 proteins and uses thereof
TW202330027A (zh) 抗ｃｄ－４７抗體製劑
CN118786144A (zh) 可活化双特异性抗cd47和抗pd-l1蛋白质及其用途
WO2024218512A1 (en) Activatable bispecific anti-cd89 and anti-pd-l1 proteins and uses thereof
WO2024218509A1 (en) Activatable bispecific anti-cd28 and anti pd-l1 proteins and uses thereof
HK40075900B (en) Pd1 and vegfr2 dual-binding agents
HK40075900A (en) Pd1 and vegfr2 dual-binding agents